Severin Schwan said his deal-making was “very agnostic” when it came to both the number of patients targeted and disease area
Caroline Copley and Ben Hirschler, The Globe and Mail
Tue, 09/16/2014 - 10:09am
Severin Schwan said his deal-making was “very agnostic” when it came to both the number of patients targeted and disease area